Evidence map›Paper›PMID 40805286›Full record

ArticleCancers2025

Auxiliary Value of [

Yafei Zhang, Mimi Xu, Shuye Yang, Lili Lin, Huatao Wang, Kui Zhao, Hong Yang, Xinhui Su

Abstract read
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yafei ZhangDepartment of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Mimi XuDepartment of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Shuye YangDepartment of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Lili LinDepartment of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Huatao WangDepartment of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Kui ZhaoDepartment of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Hong YangDepartment of Radiology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Xinhui SuDepartment of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.ORCID 0000-0002-4782-3982

Funding

Huadong Medicine Joint Funds of the Zhejiang Provincial Natural Science Foundation of China LHDMZ22H300010Major Plan of Jointly Constructed Project by the Science and Technology Department of the State Administration of Traditional Chinese Medicine and the Zhejiang Provin-cial Administration of Traditional Chinese Medicine GZY-ZJ-KJ-24025National Natural Science Foundation of China 82071965
6 · The paper itself

Abstract

BACKGROUND/

objectivesThis study aims to evaluate the additional value of [

methodsThirty-one patients with suspected recurrence of BM in LCBM after SRS were enrolled in this retrospective study. They underwent both [

resultsIn these 31 patients, there were 54 lesions, of which 27 lesions were proven to be BM recurrence, while 27 lesions were non-recurrence. [

conclusionsThis study identified that compared with CE-MRI, [

Indexed as

[18F]F-fluorocholinebrain metastasis from lung cancercontrast-enhanced MRIPET/CTstereotactic radiosurgery

Identifiers

PMID40805286
PMCPMC12345718

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.